Grantham, Mayo, Van Otterloo & Co (GMO)’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-173,001	Closed	-$22.8M	–	704
2025 Q1	$22.8M	Buy	+173,001	New	+$21.6M	0.07%	175

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s ITCI Position: Q2 2025 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 173,001 shares — an estimated $22.8M sold.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in ITCI in Q1 2025 and held it in 1 quarter. The position peaked at $22.8M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Grantham, Mayo, Van Otterloo & Co (GMO) reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Grantham, Mayo, Van Otterloo & Co (GMO) sold 173,001 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $22.8M.
Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in Intra-Cellular Therapies Inc. in Q1 2025 and held it in 1 quarter.
Grantham, Mayo, Van Otterloo & Co (GMO)'s Intra-Cellular Therapies Inc. position peaked at $22.8M in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q2 2025, filed 13 Aug 2025.